Ezetimibe
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Ezetimibe: From Hypercholesterolemia to Hyperlipoproteinemia
One-Sentence Summary
Ezetimibe is an NPC1L1 inhibitor that blocks intestinal cholesterol absorption, established as add-on therapy for hypercholesterolemia and dyslipidemia. The TxGNN model's top signal, Hyperlipoproteinemia, is supported by 80+ clinical trials and 20+ publications — but this evidence pack's own mechanistic rationale flags it as the drug's existing approved use rather than a genuinely new indication. A more novel, but much weaker, signal appears further down the ranked list (see caveat below).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in Norway regulatory filings (drug not marketed locally, 0 authorizations); literature in this pack confirms ezetimibe's established use is LDL-C-lowering / hypercholesterolemia therapy |
| Predicted New Indication | Hyperlipoproteinemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, no structured MOA field is available (original_moa: [Data Gap]), but the evidence pack's mechanistic rationale supplies the underlying pharmacology: ezetimibe selectively inhibits the NPC1L1 (Niemann-Pick C1-Like 1) transporter on the intestinal brush border, blocking absorption of dietary and biliary cholesterol. This lowers LDL-C and produces a synergistic lipid-lowering effect when combined with statins.
Important caveat: the model's rank-1 prediction, hyperlipoproteinemia, is explicitly annotated in this evidence pack's own repurposing_rationale as "the drug's existing approved indication, not a new-use signal" (原文: 此為藥物之既有核准適應症，非新用途訊號). The rank-2 prediction, familial hypercholesterolemia, is similarly described as a "standard adjunct therapy" already in clinical use — not a repurposing candidate. Both are therefore best read as model validation (TxGNN correctly recovering known indications) rather than novel repurposing opportunities.
The genuinely exploratory signal in this candidate set is rank 3, hypercholesterolemia due to CYP7A1 (cholesterol 7α-hydroxylase) deficiency — a rare monogenic bile-acid synthesis disorder where NPC1L1 blockade could theoretically reduce cholesterol/bile-acid recycling. However, this carries only L4 evidence (mechanistic extrapolation, no clinical trials) and is staged as a Research Question, not ready for further action. Rank 4 (CETP deficiency) is unsupported (L5, Hold) since that condition typically presents with elevated, not deficient, HDL-C — mechanistically disconnected from ezetimibe's action.
Clinical Trial Evidence
(Evidence for rank-1 prediction: Hyperlipoproteinemia)
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00093899 | Phase 3 | Completed | 611 | Ezetimibe/simvastatin + fenofibrate coadministration lowers cholesterol and triglycerides in mixed hyperlipidemia |
| NCT06005597 | Phase 3 | Completed | 407 | Obicetrapib + ezetimibe fixed-dose combination on top of maximal lipid-lowering therapy in HeFH/ASCVD |
| NCT01763827 | Phase 3 | Completed | 615 | Ezetimibe as active comparator vs evolocumab for LDL-C lowering |
| NCT01043380 | Phase 4 | Completed | 245 | PRECISE-IVUS: ezetimibe+statin vs statin alone on coronary plaque regression by intravascular ultrasound |
| NCT00092833 | Phase 3 | Terminated | 49 | Ezetimibe 10 mg/day open-label treatment-use study in homozygous FH / homozygous sitosterolemia |
| NCT00092560 | Phase 3 | Completed | 587 | Fenofibrate + ezetimibe coadministration efficacy/safety in mixed hyperlipidemia |
| NCT00349284 | Phase 3 | Completed | 181 | Fenofibrate vs ezetimibe vs combination in Type IIb dyslipidemia with metabolic syndrome features |
| NCT00843661 | Phase 4 | Unknown | 60 | Ezetimibe+fenofibrate vs pravastatin monotherapy in HIV patients on protease inhibitors |
| NCT03434613 | Phase 4 | Completed | 64 | Statin monotherapy vs statin/ezetimibe combination effect on hepatic steatosis in NAFLD |
| NCT04862260 | Early Phase 1 | Active, not recruiting | 3 | Exploratory cholesterol-metabolism reprogramming (ezetimibe+atorvastatin+evolocumab) in pancreatic adenocarcinoma |
Literature Evidence
(Evidence for rank-1 prediction: Hyperlipoproteinemia)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40347969 | 2025 | RCT | Lancet | TANDEM trial: obicetrapib+ezetimibe fixed-dose combination significantly reduces LDL-C |
| 41206969 | 2026 | RCT | JAMA | Oral PCSK9 inhibitor enlicitide evaluated in HeFH patients not at goal on standard lipid-lowering therapy (incl. ezetimibe) |
| 25939291 | 2015 | Review | Cardiology Clinics | Ezetimibe among established add-on therapies for familial hypercholesterolemia |
| 38599725 | 2024 | Review | Indian Heart Journal | FH underdiagnosis/undertreatment; ezetimibe's role in standard management |
| 35593194 | 2022 | Review | J Cardiovasc Pharmacol Ther | PCSK9 inhibitors reviewed against background statin/ezetimibe therapy in statin-intolerant and FH patients |
| 40682836 | 2025 | — | Molecular Medicine Reports | Review of current hyperlipidemia drug classes, including cholesterol absorption inhibitors |
| 33766264 | 2021 | — | J American College of Cardiology | New/emerging LDL-C and ApoB-lowering therapies positioned alongside ezetimibe/PCSK9i |
| 30702994 | 2019 | — | Circulation Research | Overview of cholesterol-lowering agent classes, including ezetimibe's NPC1L1 mechanism |
| 19654419 | 2009 | — | Drug and Therapeutics Bulletin | Direct review/update on ezetimibe efficacy and safety evidence at the time |
| 34480646 | 2021 | — | Current Cardiology Reports | Global burden and treatment approaches for FH, including ezetimibe |
Norway Market Information
No authorization records are present in the evidence pack — market_status = 未上市 (Not Marketed) with total_licenses = 0. Ezetimibe currently has no registered product license in Norway per available data.
Safety Considerations
Please refer to the package insert for safety information. (key_warnings, contraindications, and DDI records are all flagged as data gaps in this evidence pack, and DDI query status is not_found.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The rank-1 signal (hyperlipoproteinemia, L1 evidence) is backed by extensive Phase 3 RCT data, but this evidence pack itself identifies it as the drug's existing indication rather than a novel repurposing opportunity — so the "Proceed with Guardrails" call should be understood as validating ezetimibe's established use, not greenlighting a new indication. The one candidate that would represent genuine repurposing (CYP7A1-deficiency hypercholesterolemia, rank 3) remains at L4/Research Question stage and is not yet actionable.
To proceed, the following is needed:
- TFDA/Norwegian regulatory label data (DG001, Blocking) — required before any S1 safety pre-assessment
- Formal DrugBank MOA confirmation (DG002, High) to replace the rationale-derived mechanistic summary used here
- If pursuing the CYP7A1-deficiency signal: dedicated preclinical/mechanistic studies, since no clinical trials currently exist for this ultra-rare indication
- Re-scope the "new indication" framing for this candidate, since ranks 1–2 substantially overlap with ezetimibe's known label
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.